Blood-Brain Barrier Spheroid Model for Human-Relevant Drug Screening

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current in vitro and animal models fail to accurately recapitulate the physiological nature of the adult human blood-brain barrier, leading to high failure rates of drugs in clinical trials, and lack consideration of key cell types like neurons, microglia, and oligodendrocytes.

Innovation Solution

Development of an in vitro model comprising six cell types - astrocytes, pericytes, endothelial cells, neurons, oligodendrocytes, and microglia, formed as spheroids using a hanging drop culture protocol, which includes primary and iPSC-derived cells.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional in vitro models (mono-culture or simple co-culture) are used, then the model complexity is low and ease of manufacture is high, but the physiological relevance and reliability are insufficient

Engineering Contradiction:
Improvephysiological relevanceVSAvoidmodel complexity
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The patent combines six different cell types (endothelial cells, astrocytes, pericytes, microglia, oligodendrocytes, and neurons) into a single integrated spheroid model. This merging of multiple cell cultures creates a complex neurovascular unit that physiologically recapitulates the human blood-brain barrier, resolving the contradiction by prioritizing physiological relevance over manufacturing simplicity.

Inventive Principle:
Principle #5Merging (Combining)

Solution Approach 2:

The model employs a nested structure where endothelial cells form the core barrier layer, surrounded by astrocytes, pericytes, and other supporting cell types in concentric arrangements. This nesting principle allows multiple cell types to be organized in a physiologically accurate manner while maintaining a structured approach to model construction.

Inventive Principle:
Principle #7Nested doll (Nesting)

2Reliability

If in vivo animal models are used, then the model provides comprehensive physiological context, but the translational accuracy to human pathology is poor

Engineering Contradiction:
Improvetranslational accuracyVSAvoidhuman pathology mimicry
Core Design Contradiction:
ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent creates an in vitro copy of the human blood-brain barrier using human-derived cell types that replicate the physiological and pathological features of the human BBB. By copying human cellular components and their interactions, the model achieves high translational accuracy for human pathology without relying on animal systems.

Inventive Principle:
Principle #26Copying

Solution Approach 2:

The model uses induced pluripotent stem cells (iPSCs) derived from human patients with specific neurological conditions, allowing the physiological parameters of the BBB to reflect human pathology. This parameter change from generic cell lines to disease-specific human cells improves translational accuracy.

Inventive Principle:
Principle #35Parameter changes

3Productivity

If simple in vitro models are used, then the ease of operation and high-throughput capability are high, but the physiological nature of the adult human BBB is not recapitulated

Engineering Contradiction:
Improvehigh-throughput capabilityVSAvoidphysiological nature recapitulation
Core Design Contradiction:
ProductivityVSReliability

Solution Approach 1:

The complex six-cell type spheroid model is segmented into modular components that can be independently cultured and then assembled. This segmentation allows for standardized production of individual cell types that can be combined in high-throughput formats, maintaining both productivity and physiological relevance.

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The model transitions from traditional 2D monolayer cultures to three-dimensional spheroids, adding a spatial dimension that better recapitulates the physiological architecture of the BBB. This dimensional change enables more accurate cell-cell and cell-matrix interactions while maintaining compatibility with high-throughput screening formats.

Inventive Principle:
Principle #17Another dimension (Dimensionality change)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The model provides a high-throughput, physiologically relevant system for drug screening and toxicity testing, allowing for personalized and disease-specific assessments of agent permeability and therapeutic efficacy across the blood-brain barrier.

Implementation Method 1

culturing the cells using a hanging drop culture protocol to make the spheroid containing the six cell types

Methodology Applied
Scientific EffectSurface tension: Surface Tension

Implementation Method 2

hanging drop culture protocol

Methodology Applied
Scientific EffectGravity: Gravitation

Data Source

PatentEP3494213B1Blood brain barrier model and methods of making and using the same
Publication Date: 2026.03.25 WAKE FOREST UNIVERSITY HEALTH SCIENCES INC
  • EP3494213B1 patent drawingFigure 1
  • EP3494213B1 patent drawingFigure 2
  • EP3494213B1 patent drawingFigure 3

AI summary

Provided herein is an in vitro model of the blood brain barrier. In some embodiments, the model includes: an endothelial cell layer, and brain tissue layer comprising neuronal cells, and optionally one or more of astrocytes, pericytes, oligodendrocytes, and microglia. In some embodiments, the model further comprises a porous membrane between said endothelial cell layer and the neuronal cell layer. A microfluidic device comprising the same and methods of use thereof are also provided.